Doctor's Notes

Eczema and Child Growth: What a 1,329-Child PEDISTAD Analysis Can—and Cannot—Say

AI-generated illustration: Dr. Arsy #003 Morning Run Ritual

Dr. Arsy Editorial Team · November 9, 2026

Parents may worry that persistent eczema, sleep loss, restricted diets or treatment could affect growth. A PEDISTAD analysis described height, weight and body-mass-index percentiles in 1,329 children younger than 12 with moderate-to-severe atopic dermatitis.[3]

What the registry reported

Among children ages 5 to younger than 12, 72% of boys and 53% of girls were below the US 50th percentile for height. Weight was above the 50th percentile in 56% of boys and 52% of girls in that age range, producing above-average BMI patterns. The younger group showed a different distribution.[3]

Below the 50th percentile is not the same as growth failure

Half of a healthy reference population is expected to fall below its median. A single percentile does not show whether a child is crossing percentiles, meeting genetic expectations or growing at an appropriate velocity. The cross-sectional registry also cannot determine whether eczema caused the observed distribution.

What clinicians may consider

Growth assessment looks at repeated measurements, parental height, nutrition, puberty, chronic illness, medication exposure and laboratory evaluation when indicated. Unsupervised food elimination can reduce nutritional adequacy, particularly in young children. Families should not remove foods solely to treat eczema without a confirmed indication and appropriate guidance.[17][18]

Questions for the pediatric visit

  • Is height and weight following the child’s established curve?
  • Are itch and sleep disruption adequately controlled?
  • Has the diet become unnecessarily restrictive?
  • Are topical medicines being used as prescribed rather than avoided?
  • Is referral to dermatology, allergy, nutrition or endocrinology appropriate?

The PEDISTAD finding is a signal for thoughtful longitudinal assessment. It is not a diagnosis of impaired growth in every child with eczema.[9][10][11]

Product context

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the research above and is not a substitute for medical assessment or prescription care. Ask a pediatric clinician before using a specific product on a baby.

Related pediatric eczema research

Research and clinical references

  1. Childhood atopic dermatitis and standardized testing: US birth cohort.
  2. PEDISTAD systemic treatment outcomes by skin color.
  3. PEDISTAD growth assessment in children under 12.
  4. TREATKids clinical and molecular outcomes with dupilumab.
  5. Tapinarof efficacy by race and Fitzpatrick skin type.
  6. Atopic dermatitis and academic performance in Denmark and England.
  7. Atopic dermatitis, sleep and cognition in US adults.
  8. Eczema and educational attainment: systematic review.
  9. Pediatric atopic dermatitis guideline.
  10. AAP skin-directed management clinical report.
  11. AAAAI/ACAAI atopic dermatitis guideline.
  12. Dupilumab in children 6 months to younger than 6 years.
  13. Dupilumab in children 6 to 11 years with severe atopic dermatitis.
  14. Dupilumab in adolescents with atopic dermatitis.
  15. Tapinarof ADORING phase 3 trials.
  16. Long-term topical therapy in pediatric atopic dermatitis: ROAD study.
  17. Atopic dermatitis and child height: systematic review.
  18. Growth and nutritional status in children with atopic dermatitis.
  19. Atopic dermatitis in skin of color: clinical considerations.
  20. Racial and ethnic representation in atopic dermatitis trials.
  21. Core outcome instruments for atopic eczema.
  22. EASI validation across skin types.
  23. Patient-Oriented Eczema Measure validation in children.
  24. Atopic dermatitis quality-of-life burden in children and families.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes